SW National Pediatric Device Innovation Consortium recognizes Boppli™ platform for pediatric medical device innovation
CUPERTINO, CA and HOUSTON, TX, October 21, 2022 – The Southwest National Pediatric Device Innovation Consortium (SWPDC) awarded PyrAmes $25,000 for its Boppli platform— a non-invasive wearable sensor intended for neonatal ICU patients for continuous blood pressure monitoring with minimal skin contact, which serves as a potential alternative to arterial catheters and inflatable cuffs. The American Academy of Pediatrics (AAP) Section on Advances in Therapeutics and Technology (SOATT) annually recognizes pediatric device innovation.
A great need currently exists for medical devices designed specifically for children, which is most likely a result of economic, clinical, and regulatory challenges, as well as a lack of established mechanisms for joining pediatric device ideas with qualified individuals/programs and industry partners to create innovative and needed pediatric devices.
PyrAmes’ novel Boppli™ device enables continuous, noninvasive blood pressure monitoring (cNIBP) for the hospital’s most fragile patients.
PROVIDENCE, RI and CUPERTINO, CA, September 13, 2022 — Sentec and PyrAmes have established a commercial partnership to bring Boppli, PyrAmes’ first-of-its-kind continuous noninvasive blood pressure device, to neonatal intensive care teams throughout the United States. Boppli has received Breakthrough Device Designation from the US Food & Drug Administration (FDA) and will be available after FDA 510(k) clearance, which is anticipated in the first half of 2023.
“We are excited to join forces with Sentec to commercialize our Boppli product,” said Xina Quan, PhD, Co-Founder and CEO of PyrAmes. “This important step enables us to bring our breakthrough technology to market and transform patient care. We believe Sentec is an ideal partner for us in the NICU, given our companies’ shared mission and focus on noninvasive technologies to enable better healthcare delivery.”In the neonatal intensive care unit (NICU) today, a baby’s blood pressure is either monitored continuously through an invasive arterial catheter or intermittently through cuff measurements. Both techniques present certain clinical challenges. The Boppli™ platform offers a new solution to overcome those challenges.
PyrAmes chosen from 1,300+ applicants to collaborate with LG on innovative connected health products.
CUPERTINO, CA, February 10, 2022 -- PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced its selection by the LG Electronics North American Innovation Center, LG NOVA in its inaugural cohort of startups selected in its large-scale Mission for the Future global challenge competition. Chosen from a group of over 1,300 applicants, the “First 50” companies represent new developments in several areas including Connected Health, and will work with the LG NOVA team on their business concepts.
Plug and Play Japan and its 49 corporate partners have selected PyrAmes for its global accelerator program, including 67 companies from Japan, the U.S., Canada, India, the United Kingdom, Spain, and more. PyrAmes receives business development resources in the program’s Health track, focusing on Plug and Play’s interest in sensors and wearables.
Plug and Play Japan is a subsidiary of Plug and Play; a global innovation platform headquartered in Silicon Valley. Its major strength is to provide consortium-type programs with its extensive global network.
PyrAmes’ breakthrough blood pressure sensor is featured in Sensors, the leading international, peer-reviewed journal on the science and technology of sensors. The paper, Advances in Non-Invasive Blood Pressure Monitoring, highlights the added value of PyrAmes’ novel algorithm-based blood pressure sensor which uses machine-learning techniques to extract blood pressure values from the shape of the pulse waveform. The paper reports results from preliminary studies on a range of patient populations and discusses the accuracy and limitations of this capacitive-based technology and its potential application in hospitals and communities.
Cupertino, CA, -- (Marketwired - April 20, 2021) –PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced the completion of a $6 million Series A financing. The investment round was led by GSR Ventures, with co-investments from Keytone Ventures, XTX Ventures and other investors.
PyrAmes Inc. is proud to announce that the FDA has granted Breakthrough Device Designation (BDD) to Boppli™, which fills the unmet need of monitoring the blood pressure of critically ill infants when an invasive arterial catheter cannot be used due to the risk of complications and adverse effects.
PyrAmes is honored to be selected by the Southwest National Pediatric Device Innovation Consortium (SWPDC) as a winner of the SWPDC Spring Competition. The SouthWest National Pediatric Device Innovation Consortium (SWPDC) is a “free no-strings-attached” virtual accelerator based at Texas Children’s Hospital and Baylor College of Medicine that supports pediatric device innovators nationwide throughout the pediatric device life cycle. The goal of the SWPDC is to accelerate commercialization and clinical use of novel pediatric devices.
PyrAmes is pleased to announce it has been awarded a Phase I grant from the National Institutes of Health. The Grant will be used for ongoing product development as well as clinical validation studies. A key objective of the NIH Grant Program is to facilitate development of promising medical technologies. The content of this announcement is solely the responsibility of the author and does not necessarily represent the official views of the NIH.